$25bn-plus trade sharpens pharma giants’ focus
Friday, April 25, 2014 - 08:20
in Mathematics & Economics
Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process
Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process